J.P. Morgan Healthcare Conference

Refine Search

South Korea’s Celltrion has announced the next phase of its strategic transformation from a developer of the world's first monoclonal antibody (MAb) biosimilar to an innovative company focused on new drug development at the 42nd Annual JP Morgan Healthcare Conference in San Francisco, California. 15 January 2024

Pharmaceutical

Amgen could compete with established leaders in obesity, says analyst

Earlier this month US biotech major Amgen presented at the JP Morgan’s 42nd Annual Healthcare Conference, highlighting its pillars of business. 15 January 2024

Biotechnology

Ayvakit central to Blueprint’s 2024 plans

Blueprint Medicines Corporation has outlined its 2024 corporate strategy, promising accelerated revenue growth, sustainable research and development, and a clear path to profitability. 9 January 2024

Biotechnology

GSK to acquire Aiolos Bio and its biologic asthma candidate

UK pharma major GSK has entered into an agreement to acquire Anglo-American biotech Aiolos Bio, a clinical-stage company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions. 9 January 2024

Biotechnology

Merck expands oncology pipeline with Harpoon acquisition

US pharma giant Merck & Co entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon Therapeutics for $23.00 per share. 9 January 2024

Biotechnology

J&J wagers $2 billion to acquire Ambrx

Kicking of the JP Morgan Healthcare conference this morning, Johnson & Johnson announced a definitive agreement to acquire Ambrx Biopharma. 8 January 2024

Biotechnology

Mersana updates on expected milestones and JPM presentations

Mersana Therapeutics today announced business updates, its expected milestones and its upcoming presentation at the 42nd Annual JP Morgan Healthcare Conference. 5 January 2024

Pharmaceutical

Amgen could compete with established leaders in obesity, says analyst

Earlier this month US biotech major Amgen presented at the JP Morgan’s 42nd Annual Healthcare Conference, highlighting its pillars of business. 15 January 2024

Biotechnology

Ayvakit central to Blueprint’s 2024 plans

Blueprint Medicines Corporation has outlined its 2024 corporate strategy, promising accelerated revenue growth, sustainable research and development, and a clear path to profitability. 9 January 2024

Biotechnology

GSK to acquire Aiolos Bio and its biologic asthma candidate

Biotechnology

Merck expands oncology pipeline with Harpoon acquisition

US pharma giant Merck & Co entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon Therapeutics for $23.00 per share. 9 January 2024

Biotechnology

J&J wagers $2 billion to acquire Ambrx

Kicking of the JP Morgan Healthcare conference this morning, Johnson & Johnson announced a definitive agreement to acquire Ambrx Biopharma. 8 January 2024

Biotechnology

Mersana updates on expected milestones and JPM presentations

Mersana Therapeutics today announced business updates, its expected milestones and its upcoming presentation at the 42nd Annual JP Morgan Healthcare Conference. 5 January 2024

J.P. Morgan Healthcare Conference

Today's issue

Company Spotlight